Table 2. Clinical, laboratory and outcome findings of patients treated in ICU with COVID-19
Abbreviations: COVID 19, Corona Virus Disease 2019 caused by SARS-CoV-2; ICU, intensive care unit; NOAF, new onset atrial fibrillation; IQR, interquartile range; AKI, acute kidney injury; RRT, renal replacement therapy; LV, left ventricle; LVSD, left ventricular systolic dysfunction; ECMO, ;d, days.
Data are presented as n (%), or n/N (%) unless specified as median (IQR). P values indicate difference between patients with NOAF and those without NOAF in ICU. P<0.05 was considered statistically significant.
*Echocardiography was only performed in 90 patients (16 NOAF group and 74 without NOAF group) and the percentage is expressed accordingly.
** Only 2 patients received therapeutic anticoagulation for NOAF based on CHA2DS2 VASc score in the ICU setting.
*** Therapeutic anticoagulation commenced in some patients with high thrombotic risk based on clinical assessment and with extremely elevated D-Dimer levels in the context of COVID-19 (7 patients).